Merck Clinical Trials Logo Merck Clinical Trials

Clinical Trial Finder

Merck Clinical Trial Finder

Trial Age: Adult (18–64)

The purpose of this study is to evaluate the efficacy and safety of MK-0616, an oral PCSK9 inhibitor, in lowering low-density lipoprotein cholesterol (LDL-C) in participants with hypercholesterolemia. The primary hypothesis is that at least one of the four doses of MK-0616 tested in this study is superior to placebo on percent change from baseline in LDL-C at Week 8.

A Study of the Efficacy and Safety of MK-0616 in Adults With Hypercholesterolemia

March 25, 2022

By Joe Kowalczyk

The purpose of this study is to evaluate the efficacy and safety of MK-0616, an oral PCSK9 inhibitor, in lowering low-density lipoprotein cholesterol (LDL-C) in participants with hypercholesterolemia. The primary hypothesis

Safety, Tolerability, and Immunogenicity of V110 or V114 Co-administered With a Booster Dose of mRNA-1273 in Healthy Adults

February 23, 2022

By clique_admin

The purpose of this study is to evaluate the concomitant and non-concomitant use of messenger ribonucleic acid (mRNA) mRNA-1273, the nucleoside-modified mRNA vaccine for active immunization to prevent coronavirus disease (COVID-19)

A Study to Assess Contraceptive Efficacy and Safety of Etonogestrel Implant Beyond 3 Years of Use

December 1, 2021

By clique_admin

The primary purpose of this study is to assess the efficacy and safety of the etonogestrel (ENG) contraceptive implant during participants’ fourth and fifth years of use when used as the

A Study of Vericiguat in Participants With Chronic Heart Failure With Reduced Ejection Fraction

November 12, 2021

By clique_admin

The purpose of this study is to evaluate the efficacy and safety of vericiguat in participants with chronic heart failure with reduced ejection fraction (HFrEF), specifically those with symptomatic chronic HFrEF

A Study of the Efficacy and Safety of MK-5475 in Participants With Pulmonary Arterial Hypertension

November 12, 2021

By clique_admin

This is a two-part (Phase 2/Phase 3) study of MK-5475, an inhaled soluble guanylate cyclase stimulator, in participants with pulmonary arterial hypertension (PAH). The first part (Phase 2) will assess three

Efficacy and Safety of MK-8189 in Participants With an Acute Episode of Schizophrenia

November 12, 2021

By clique_admin

The purpose of this study is to evaluate the efficacy and safety of MK-8189 at a range of doses (8 mg, 16 mg, and 24 mg once daily) in adult participants

Efficacy and Safety of Gefapixant in Women With Chronic Cough and Stress Urinary Incontinence

November 12, 2021

By clique_admin

The purpose of this study is to evaluate the efficacy and safety of gefapixant, in improving symptoms of cough-induced stress urinary incontinence (SUI) in adult female participants with refractory or unexplained

Efficacy and Safety of MK-1942 When Added to Stable Antidepressant Therapy in Participants With Treatment-Resistant Depression

November 12, 2021

By clique_admin

The main purpose of this study is to assess the efficacy and safety of daily and intermittent dosing of MK-1942 compared to placebo among participants with Treatment-Resistant Depression (TRD) on a

Study of MK-4482 for Prevention of Coronavirus Disease 2019 in Adults

November 12, 2021

By clique_admin

The primary objectives of this phase 3, multicenter, randomized, double-blind, placebo-controlled study are to determine the efficacy, safety, and tolerability of molnupiravir (MK-4482) compared with placebo for the prevention of laboratory-confirmed

MK-1942/Donepezil Interactions in Participants With Alzheimer’s Disease

November 12, 2021

By clique_admin

The study will investigate the effects on safety and pharmacokinetics (PK) of MK-1942 and donepezil when co-administered to participants with Alzheimer’s Disease with mild-to-moderate cognitive impairment stably treated with donepezil. The

Posts navigation

Older posts
Merck Clinical Trials Logo Merck Clinical Trials
  • Merck.com
  • Privacy Policy
  • Terms of Use
  • Policies & Perspectives
  • Cookie Preferences
  • Accessibility

Copyright © 2022 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved.

THIS WEBSITE IS INTENDED FOR A UNITED STATES AUDIENCE ONLY

Merck Essential Accessibility

Merck Essential Accessibility